Director/PDMR Shareholding

RNS Number : 5402A
Tepnel Life Sciences PLC
04 August 2008

Tepnel Life Sciences plc ("Tepnel" or the "Company")

Director holdings

Manchester, UK - 4 August 2008 Tepnel Life Sciences PLC (AIM: TED), the UK-based international Molecular Diagnostics and Research
Products & Services group, was informed on 31 July 2008 that Alec Craig, Non-Executive Chairman, purchased 750,000 ordinary shares in the
Company on 31 July 2008 at 9.97p each.

Mr Craig is now interested in 1,750,000 ordinary shares representing approximately 0.76 per cent. of the ordinary issued share capital
of the Company.

The Company was informed on 31 July 2008 that Michael Slater, Group Finance Director, purchased 100,000 ordinary shares in the Company
on 31 July 2008 at 10.25p each.

Mr Slater is now interested in 100,000 ordinary shares representing approximately 0.04 per cent. of the ordinary issued share capital of
the Company.

The Company was informed on 31 July 2008 that Dr. Andrew Clark, Non-Executive Director, purchased 100,000 ordinary shares in the Company
on 31 July 2008 at 10.13p each.

Dr. Clark is now interested in 1,161,000 ordinary shares representing approximately 0.50 per cent. of the ordinary issued share capital
of the Company.

For Further Information:

Tepnel Life Sciences plc
Ben Matzilevich, CEO
Michael Slater, Group Finance Director
Carol Smith, Group Marketing Communications Manager
0161 946 2200

Capital MS&L
Mary Clark or Joey Whineray
Tel: +44 20 7307 5330

Seymour Pierce Limited
Mark Percy
Tel: +44 20 7107 8000

Notes to Editors

About Tepnel Life Sciences plc
Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences products and services group with two main divisions, Molecular
Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France over 200
employees. Tepnel provides test kits, reagents and services to two highly synergistic markets, these being Molecular Diagnostics and
Biomedical Research. The Company's strategy has been to identify high growth niche opportunities within these multi-billion pound markets.
Tepnel focuses on these niche opportunities with internally developed products, patents, expertise and know-how as well as strategic
acquisitions, to develop a leadership position within these defined market segments.

This information is provided by RNS
The company news service from the London Stock Exchange

END

RDSGIGDIGGGGGIS

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024